Small cell synergy

Investors and others watching data coming from the American Society of Clinical Oncology meeting were quick to pan overall survival data from a Phase I study of single-agent Rova-T rovalpituzumab tesirine in recurrent small cell lung cancer. But AbbVie Inc. is expecting to extract value from the antibody-drug conjugate through combinations with chemotherapy and immunotherapies.

"Our strategy has been to demonstrate single agent activities first, then move into combinations, and so that's what we're doing with small cell," said Chairman and CEO Richard Gonzalez during AbbVie's R&D day on June 3...